menu
    • menu
    [{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Hawaii Pacific Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-ATN1-002","moa":"ATN1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ Hawaii Pacific Neuroscience","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Hawaii Pacific Neuroscience"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-CHCHD-001","moa":"CHCHD10","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Columbia University"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-CHCHD-001","moa":"CHCHD10","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Columbia University"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"The Methodist Hospital Research Institute | Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-TARD-001","moa":"TDP43","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ The Methodist Hospital Research Institute | Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ The Methodist Hospital Research Institute | Columbia University"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Hongene Biotech","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"n-Lorem Foundation \/ n-Lorem Foundation","highestDevelopmentStatusID":"3","companyTruncated":"n-Lorem Foundation \/ n-Lorem Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"The Conrad Prebys Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"n-Lorem Foundation \/ The Conrad Prebys Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Foundation \/ The Conrad Prebys Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Parexel Biotech","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"n-Lorem Foundation \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Foundation \/ n-Lorem Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Argonaut Manufacturing Services","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"n-Lorem Foundation \/ n-Lorem Foundation","highestDevelopmentStatusID":"1","companyTruncated":"n-Lorem Foundation \/ n-Lorem Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Cytiva","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Foundation \/ n-Lorem Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Foundation \/ n-Lorem Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"St. Jude Children","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Foundation \/ n-Lorem Foundation"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"GondolaBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ GondolaBio","highestDevelopmentStatusID":"3","companyTruncated":"n-Lorem Foundation \/ GondolaBio"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-PRPH2-001","moa":"PRPH2","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ University of California, San Diego","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ University of California, San Diego"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"University of North Carolina, Chapel Hill","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-ASXL3-001","moa":"ASXL3 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ University of North Carolina, Chapel Hill","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ University of North Carolina, Chapel Hill"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-MAPK8-001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Columbia University"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Dell Children's Medical Center of Central Texas","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-ATN1-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"n-Lorem Foundation \/ Dell Children's Medical Center of Central Texas","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Dell Children's Medical Center of Central Texas"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-GARS1-001","moa":"GARS1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ University of Texas Health Science Center at Houston"}]

    Find Clinical Drug Pipeline Developments & Deals by n-Lorem Foundation

    Menu

    n-Lorem Foundation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-GARS1-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of Texas Health Science Center at Houston

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charc...

                            Details : NL-GARS1-001 is an oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Charcot-Marie-Tooth Disease.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 10, 2025

                            Lead Product(s) : nL-GARS1-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of Texas Health Science Center at Houston

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-ATN1-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Dell Children's Medical Center of Central Texas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide for ATN1 Gene Mutation Patient

                            Details : NL-ATN1-001 is an oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Myoclonic Epilepsies, Progressive.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 28, 2025

                            Lead Product(s) : nL-ATN1-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Dell Children's Medical Center of Central Texas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-ASXL3-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of North Carolina, Chapel Hill

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation

                            Details : NL-ASXL3-001 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Bainbridge-Ropers Syndrome.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 29, 2025

                            Lead Product(s) : nL-ASXL3-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of North Carolina, Chapel Hill

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-MAPK8-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With...

                            Details : NL-MAPK8-001 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neurodevelopmental Disorders.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 29, 2025

                            Lead Product(s) : nL-MAPK8-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-PRPH2-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Re...

                            Details : NL-PRPH2-001 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Retinal Dystrophies.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 16, 2025

                            Lead Product(s) : nL-PRPH2-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-CHCHD-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide for Participants with CHCHD10 ALS

                            Details : NL-CHCHD-001 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 31, 2025

                            Lead Product(s) : nL-CHCHD-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-TARD-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : The Methodist Hospital Research Institute | Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide Therapy for A Single Participant with TARDBP ALS

                            Details : NL-TARD-001 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 31, 2025

                            Lead Product(s) : nL-TARD-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : The Methodist Hospital Research Institute | Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-ATN1-002

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hawaii Pacific Neuroscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide for A Single Participant with ATN1 Gene Mutation

                            Details : NL-ATN1-002 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Myoclonic Epilepsies, Progressive.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 24, 2025

                            Lead Product(s) : nL-ATN1-002

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hawaii Pacific Neuroscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nL-CHCHD-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Antisense Oligonucleotide for a Single Participant with CHCHD10 ALS

                            Details : NL-CHCHD-001 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 18, 2025

                            Lead Product(s) : nL-CHCHD-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            n-Lorem Foundation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Sponsor : GondolaBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GondolaBio, n-Lorem Partner for ASO Therapies for Genetic Disease Advancement

                            Details : The collaboration aims to discover novel antisense oligonucleotide (ASO) medicines for patients who are not currently served by available treatment options.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 17, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Sponsor : GondolaBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth